Skip to main content

12-06-2018 | Spondyloarthropathies | News

News in brief

Secukinumab treatment does not compromise systemic immune response in SpA patients

medwireNews: Treatment with the interleukin(IL)-17A inhibitor secukinumab leads to clinical improvement of spondyloarthritis (SpA) and immunomodulation in target tissues without having a negative effect on the systemic immune response, researchers report.

In an open-label trial, 65% of 20 patients with peripheral SpA who were treated with secukinumab (300 mg/week for 4 weeks followed by every 4 weeks thereafter) experienced at least a 20% improvement in ACR criteria by the 12-week follow-up.

Histopathologic analysis revealed that this clinical response was accompanied by a significant decrease in CD15+ neutrophils and synovial sublining CD68+ macrophages, which are “both sensitive biomarkers for synovial inflammation in SpA,” explain Leonieke van Mens (University of Amsterdam, the Netherlands) and co-investigators.

However, with the exception of IL-17A itself, secukinumab treatment did not affect the ability of peripheral blood cells to produce a range of 30 different cytokines and chemokines, including “key host defense factors” such as tumor necrosis factor alpha and interferon gamma.

These findings indicate that “IL-17A blockade with secukinumab has a profound clinical and immunopathological impact on [peripheral] SpA without compromising systemic immune responses,” conclude the researchers in Arthritis & Rheumatology.

By Claire Barnard

medwireNews is an independent medical news service provided by Springer Healthcare. © 2018 Springer Healthcare part of the Springer Nature group

Related topics

Repurposing rheumatology drugs for COVID-19

Experts discuss the rationale, data on different agents, and the potential impact on rheumatology practice.

  • » Featuring insights from the COVID-19 Global Rheumatology Alliance, EULAR, and the Lupus Foundation of America
Image Credits